Spark Crowdfunding’s Post

One of our portfolio companies, Altach (an NLC Venture), has secured a €1.2 million investment. This capital injection will help Altach enhance their work in developing treatments for cartilage injuries, which are a major cause of osteoarthritis. Big congratulations to the CEO of Altach, Tomir Kosowski, CTO and one of the inventors, David Browe, and the rest of the Altach team for achieving this important milestone!  🔬 𝐀𝐛𝐨𝐮𝐭 𝐭𝐡𝐞 𝐭𝐞𝐜𝐡𝐧𝐨𝐥𝐨𝐠𝐲: Altach, which started at Trinity College Dublin in 2022, has created a new type of scaffold that mimics natural cartilage. This can help the body heal faster and more effectively than traditional methods. 🌍 𝐌𝐚𝐫𝐤𝐞𝐭 𝐢𝐦𝐩𝐚𝐜𝐭: With over 600,000 cartilage repair procedures each year in the US alone, and a market expected to grow to $5.9 billion by 2031, the impact of Altach's technology is significant. 📈 𝐈𝐧𝐯𝐞𝐬𝐭𝐨𝐫 𝐬𝐮𝐩𝐩𝐨𝐫𝐭: This round of funding includes contributions from Spark Crowdfunding, NLC’s Stepping Stone Fund, Castanjo B.V., and two angel investors. Want to learn more about the impact of Altach’s work? Read the full article on Silicon Republic. 👇🏼 #NLC #impactinvesting #healthtech https://lnkd.in/eC_gmsWe

⏰ [D-7] There's just one week left to take advantage of the Early Bird bonus 🦅 from our crowdfunding campaign: investments made before August 15 qualify for a bonus in shares. Shares awarded are calculated on a valuation of €23 million instead of 24! To invest 💶 , follow the link! ⏬ https://lnkd.in/dyBSg93p #startup #crowdfunding #medtech #biotech

Early results from their Golden Retriever model, which mirrors Duchenne muscular dystrophy in humans, show promising reductions in creatinine kinase markers, indicating potential efficacy. Read more 👉 https://lttr.ai/AUkf7 #Crowdfunding #Equitycrowdfunding #Marketing #SocialMedia #Community #ImprovePatientsQuality #ShowPromisingReductions #crowdfunding #equitycrowdfunding

This $66m oversubscribed series B for ShiraTronics, Inc. brings the yearly subtotal raised in #neuromodulation to $618 million. That's +10% on this time last year, and a significant increase on the 2022 numbers. Yes, in many ways, and for many reasons this has been a challenging year, however you can't ignore this continued, and increasing interest in #neurotech from investors. Any start-ups in this space currently raising, or planning to raise should be encouraged by these stats. IMO there is no other area of #medtech that comes close to the sheer potential that Neuromod presents. Norwest Venture Partners led this investment round, and Shiratronics will use the funds to support their recently launched pivotal trial "RELIEV-CM2” to evaluate their Migraine Therapy System. The fnancing is also intended to fund initial commercial launch as they seek FDA PMA. Big congratulations to Rob Binney and the Shiratronics gang. UPDATED: Just seen a $27m raise from Nyxoah too. That's some 24hrs for Neuromod. Congratulations all

⏱️ The Countdown Begins Cytonics Corporation's crowdfund campaign closes soon. You have 2 more opportunities to chat with our CEO and make a final investment decision. 🔗 invest.cytonics.com 📅  The Final Countdown As we approach the culmination of our groundbreaking equity crowdfunding campaign, we want to remind you that the opportunity to invest in Cytonics will officially close on May 28, 2024 @ 11:59pm PST (May 29th @ 3am EST). This marks not just the end of a phase but the beginning of an exciting new chapter in our journey towards revolutionizing osteoarthritis therapy. 🧑💼 Pow Wow With Our CEO To ensure that all potential investors have the chance to learn more about our innovative approach and the impact of your investment, we are hosting two final webinars: May 23, 2024 @ 4 PM EST: https://lnkd.in/eVqecxgz May 28, 2024 @ 12 PM EST: https://lnkd.in/e5snw7Q2 These webinars will provide insights into the development of our novel therapy  for osteoarthritis, our strategy for increasing shareholder value, and how your investment can contribute to a revolution in regenerative medicine. ⏰ Before The Clock Strikes Midnight This is your last chance to invest in this offering and benefit from being part of a venture that aims to bring lasting relief to the millions suffering from joint damage worldwide. Act now to ensure you don’t miss out on this investment opportunity before it’s too late. Remember, once the clock strikes 11:59:59pm PST on May 28th (May 29th at 3am EST), the opportunity to invest under these terms will be gone forever! 🪙 Invest today to be part of a future where we redefine the treatment of osteoarthritis. Let's make a difference together. #biotechnology #arthritis #osteoarthritis #investing #crowdfunding #venturecapital #healthcare #drugdevelopment #clinicaltrials #regenerativemedicine #orthopedics #orthopaedics #surgery #investor #FDA #medicine #lifesciences #researchanddevelopment #capitalmarkets

Collaboration in the non-profit sector is key to actually solving problems (whatever the societal issue). I love what the Reeve Foundation is doing with this new venture fund with others in SCI research …… #collaboration #venturefund

🦾 Our Army Of 5,000 Shareholders Is Growing By The Day... Discover how our army of loyal Cytonics Corporation shareholders is propelling us towards revolutionizing regenerative medicine! 🖇 invest.cytonics.com 💸 Fundraising Triumphs: A Collective Achievement To date, we have raised over $25M in pursuit of developing the first and only therapy for osteoarthritis. This monumental effort boasts: ➡️ A $4M investment from Synthes (a medical device company acquired by Johnson and Johnson for $19B), alongside ➡️ $10M raised through equity crowdfunding, with ➡️ Over 100 orthopedic surgeons who utilize our APIC therapy for osteoarthritis and understand the significance of our drug development program. Our Cytonics family has expanded to over 5,000 shareholders who have played a pivotal role in our success through repeat investment, an outpouring of encouragement, and spreading the word. Every investor, regardless of the size of their committment, is a part of our family and treated as such. The current round has welcomed over 1,100 new shareholders, many of whom are placing their first equity crowdfunding investment (292 to be exact)! 🔍 A Closer Look Into Our Campaign The unwavering loyalty and commitment of our shareholders is a testament to the deep trust and shared goals that bind us. This round alone has raised over $2.7M from more than 1,100 investors, 60% of whom are returning shareholders. This remarkable rate of recurring investment is not just a metric of success but a beacon of the belief in our mission, confidence in management, and the impact of our research. ❤️ In Gratitude Your continued support and belief in Cytonics are more than just a financial decision; you are the driving force behind our relentless pursuit of improving human well-being. It's a shared journey towards creating long-term value and making a significant impact on the lives of those affected by osteoarthritis. #biotechnology #arthritis #investing #crowdfunding #venturecapital #healthcare #drugdevelopment #clinicaltrials #regenerativemedicine

🦾 Our Army Of 5,000 Shareholders Is Growing By The Day... Discover how our army of loyal shareholders is propelling us towards revolutionizing regenerative medicine! 🖇 invest.cytonics.com 💸 Fundraising Triumphs: A Collective Achievement To date, we have raised over $25M in pursuit of developing the first and only therapy for osteoarthritis. This monumental effort boasts: ➡️ A $4M investment from Synthes (a medical device company acquired by Johnson and Johnson for $19B), alongside ➡️ $10M raised through equity crowdfunding, with ➡️ Over 100 orthopedic surgeons who utilize our APIC therapy for osteoarthritis and understand the significance of our drug development program. Our Cytonics family has expanded to over 5,000 shareholders who have played a pivotal role in our success through repeat investment, an outpouring of encouragement, and spreading the word. Every investor, regardless of the size of their committment, is a part of our family and treated as such. The current round has welcomed over 1,100 new shareholders, many of whom are placing their first equity crowdfunding investment (292 to be exact)! 🔍 A Closer Look Into Our Campaign The unwavering loyalty and commitment of our shareholders is a testament to the deep trust and shared goals that bind us. This round alone has raised over $2.7M from more than 1,100 investors, 60% of whom are returning shareholders. This remarkable rate of recurring investment is not just a metric of success but a beacon of the belief in our mission, confidence in management, and the impact of our research. ❤️ In Gratitude Your continued support and belief in Cytonics are more than just a financial decision; you are the driving force behind our relentless pursuit of improving human well-being. It's a shared journey towards creating long-term value and making a significant impact on the lives of those affected by osteoarthritis. #biotechnology #arthritis #investing #crowdfunding #venturecapital #healthcare #drugdevelopment #clinicaltrials #regenerativemedicine

We are incredibly grateful for our brilliant investors! Take a moment to learn more about our recent investment round and a brief update on our clinical trial progress with the University of Bath and Royal United Hospitals Bath NHS Foundation Trust! Email the team to find out more about our transformative results. 📩 - info@preactiv.co.uk #ClinicalTrial #investments #Prehab #Preactiv #innovation #healthtech

Ahammune Biosciences Pvt. Ltd., a Pune-based biotech startup, has raised $5 million in a Series A funding round led by pi Ventures, an early-stage venture capital fund. The funding round saw participation from Capital 2B, Colossa Ventures, Bipin Agarwal, Unicornus Maximus LLP, and existing investors such as Ideaspring Capital, Kotak Alternate Asset Managers Limited, Legacy Assets LLP, and IAN Group (formerly Indian Angel Network). Founded in 2016 by Dr. Parul Ganju and Dr. Natarajan Krishnamurthy, Ahammune Biosciences aims to become a leader in the dermatological drug discovery space by developing innovative treatments for conditions that impact patients worldwide. Read more at: https://lnkd.in/gw7Fxz82 #biotech #startupfunding #dermatology #drugdiscovery #seriesafunding #innovation #healthcare #vitiligo #entrepreneurship #lifesciences #medicalresearch #healthtech #startupstory